Abstract:BACKGROUND: Immunotherapy combined with chemotherapy has been shown to be efficacious as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without targetable genetic aberrations; however, there is scarce evidence of the effectiveness of the combinations in the Asian population. We evaluated camrelizumab plus chemotherapy against non-squamous NSCLC in China.METHODS: We did a randomised, open-label, multicentre, phase 3 trial (CameL) in 52 hospitals in China for patients with non-squamous NSCLC without EGFR and ALK alteration. Eligible patients were aged 18-70 years and had no previous systemic chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, and at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (version 1.1). Patients were randomly assigned (1:1) to receive 4-6 cycles of carboplatin (area under curve 5 mg/mL per min) plus pemetrexed (500 mg/m<sup>2</sup>) with or without camrelizumab (200 mg) every 3 weeks, followed by maintenance therapy with camrelizumab plus pemetrexed or pemetrexed alone. Medication was administered intravenously on day 1 of each 3-week treatment cycle. Randomisation was done using a centralised interactive web-response system with the block size randomly generated as four or six and stratified by sex and smoking history. The two primary endpoints were progression-free survival per blinded independent central review, in all patients and in patients who were PD-L1 positive. Primary analysis was done in the full analysis set that included all randomly assigned patients who received at least one dose of the study treatment. Herein, due to the primary endpoint being met at the interim analysis, we reported the findings of prespecified interim analysis, which only included confirmatory statistical testing for progression-free survival in all patients. Safety was assessed in the as-treated population. This study is registered with ClinicalTrials.gov, NCT03134872 (follow-up is ongoing).FINDINGS: Between May 12, 2017, and June 6, 2018, of the 419 patients who were randomly assigned, seven did not receive assigned treatment and 412 received either camrelizumab plus chemotherapy (n=205) or chemotherapy alone (n=207). At interim analysis, median follow-up duration was 11·9 months (IQR 9·0-14·9). Progression-free survival in this interim analysis was significantly prolonged with camrelizumab plus chemotherapy than with chemotherapy alone (median 11·3 months [95% CI 9·6-15·4] vs 8·3 months [6·0-9·7]; hazard ratio 0·60 [0·45-0·79]; one-sided p=0·0001). Most common grade 3 or worse treatment-related adverse events were decreased neutrophil count (78 [38%] patients in the camrelizumab plus chemotherapy group vs 63 [30%] patients in the chemotherapy alone group), decreased white blood cell count (40 [20%] vs 30 [14%]), anaemia (38 [19%] vs 23 [11%]), and decreased platelet count (34 [17%] vs 24 [12%]). Serious treatment-related adverse events occurred in 74 (36%) patients in the camrelizumab plus chemotherapy group and 27 (13%) patients in the chemotherapy alone group.INTERPRETATION: The primary endpoint was met at the interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in all patients, supporting camrelizumab plus carboplatin and pemetrexed as a first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations. The trial is being continued to collect long-term outcomes in all patients and carry out confirmatory statistical testing for progression-free survival in the PD-L1-positive population.FUNDING: Jiangsu Hengrui Medicine.

P2.06-04 First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).

A clinical study of camrelizumab combined with chemotherapy and sequential apatinib in the second-line treatment of patients with advanced non-small cell lung cancer.

Camrelizumab in Different PD-L1 Expression Cohorts of Pre-Treated Advanced or Metastatic Non-Small Cell Lung Cancer: a Phase II Study.

OA04.03 A Randomized Phase 3 Study of Camrelizumab Plus Chemotherapy As 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo Vs Chemo for Advanced Non-Squamous NSCLC

Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma.

P2.14-07 Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin As First-Line Treatment for ES-SCLC: A Phase II Trial

Camrelizumab Plus Apatinib for Immunochemotherapy-Treated Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of Cohort 2 in CAP 02 Study.

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study

Camrelizumab Combined with Capecitabine and Oxaliplatin Followed by Camrelizumab and Apatinib As First-Line Therapy for Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: Updated Results from a Multicenter, Open Label Phase II Trial.